Biotech - Gene Therapy
•108 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (108)
%
| Company | Market Cap | Price |
|---|---|---|
|
Gene therapy modality and collaborations (Verve Therapeutics) indicate Lilly's gene therapy focus.
|
$789.93B |
$833.49
-2.86%
|
|
Gene therapy is a major differentiator for Novartis with programs like Zolgensma and OAV-101 IT.
|
$252.00B |
$130.00
|
|
CASGEVY uses gene-editing (CRISPR/Cas9) technology, placing it in the gene therapy category.
|
$104.72B |
$407.79
-1.34%
|
|
Biotech - Gene Therapy covers Regeneron’s gene-therapy efforts like DB-OTO and broader genetic medicine approaches.
|
$60.96B |
$564.63
-0.82%
|
|
INS1201 is a gene therapy program, aligning Insmed with the Gene Therapy investable theme.
|
$29.57B |
$162.33
-1.08%
|
|
Gene therapy programs with Voyager Therapeutics indicate a gene therapy Biotech modality within Neurocrine’s pipeline.
|
$14.51B |
$146.95
+0.38%
|
|
Ionis pursues gene therapy collaborations and related modalities, indicating engagement with gene-editing/gene-therapy approaches beyond antisense.
|
$11.14B |
$69.97
-0.04%
|
|
BBP-812 is an AAV9 gene therapy for Canavan disease, directly produced by BridgeBio.
|
$10.54B |
$55.49
+1.20%
|
|
DCI's Life Sciences activities include manufacturing-grade IsoTag AAV reagent for GMP bioprocessing, a concrete product line.
|
$9.31B |
$79.88
-2.06%
|
|
Biotech - Gene Therapy reflects Bio-Techne's involvement in cell and gene therapy platforms and enabling technologies.
|
$8.72B |
$55.63
+6.51%
|
|
CRISPR Therapeutics' core business is gene-editing therapies (ex vivo CASGEVY) and related gene-editing platforms.
|
$6.31B |
$73.07
-5.51%
|
|
Involves gene-modified cell therapies and development of gene therapy–related platforms (e.g., in vivo delivery).
|
$5.82B |
$31.70
-1.22%
|
|
Upstaza/Kebilidi gene therapy is a direct gene therapy product, placing the company in the Gene Therapy category.
|
$5.25B |
$66.23
+0.23%
|
|
Krystal's HSV-1 gene therapy platform and lead product VYJUVEK are gene therapies targeting rare diseases.
|
$5.24B |
$181.47
-4.43%
|
|
Akero is a biotechnology company focused on developing therapeutic biologics for metabolic diseases.
|
$4.30B |
$53.88
-0.39%
|
|
uniQure directly develops AAV-based gene therapies and its proprietary miQURE silencing technology, which are the core products/services it provides.
|
$3.01B |
$54.50
-2.45%
|
|
Directly develops and commercializes gene therapies using AAV vectors for rare diseases, covering programs like UX111, DTX401, UX701, UX143, and GTX-102.
|
$2.97B |
$31.45
-1.13%
|
|
Beam Therapeutics is built around a gene therapy platform (base editing) and develops therapeutic programs that edit genes to treat diseases.
|
$2.65B |
$26.32
-7.58%
|
|
CAR-T and associated gene-editing components position the company within the broader gene therapy landscape.
|
$2.25B |
$34.10
+0.86%
|
|
Directly develops and commercializes gene therapies (ELEVIDYS) and gene-targeted modalities; core product category in Sarepta's business.
|
$2.17B |
$22.11
-4.49%
|
|
Intellia's core offerings are in vivo CRISPR gene therapy programs, representing Biotech - Gene Therapy.
|
$1.69B |
$16.31
-1.33%
|
|
TANGO platform involves upregulating healthy gene expression, aligning with gene therapy/modulation paradigms.
|
$1.65B |
$30.19
-2.46%
|
|
FORCE platform enables targeted delivery of genetic payloads to muscle/CNS, making Dyne a direct developer of gene therapy–like therapeutics.
|
$1.60B |
$14.05
-0.57%
|
|
AMX0114 is an antisense oligonucleotide targeting CAPN2, representing a gene-therapy–type modality.
|
$1.27B |
$14.26
-1.11%
|
|
Wave Life Sciences develops RNA-based therapeutics and gene-editing approaches (AIMers, allele-selective therapies), directly matching gene therapy as its core offering.
|
$1.17B |
$7.60
-8.21%
|
|
HCAd gene therapy platform and PCRX-201 OA program, plus the GQ Bio Therapeutics acquisition, anchor a gene-therapy product pipeline.
|
$1.17B |
$25.24
-2.28%
|
|
Genetic modification of T cells places Immatics within Biotech - Gene Therapy.
|
$1.07B |
$10.36
-5.39%
|
|
Direct product: TSHA-102 is a gene therapy using an AAV9 vector designed to address Rett syndrome.
|
$1.01B |
$4.81
+1.91%
|
|
Verve Therapeutics is developing in vivo gene-editing therapies (GalNAc-LNP delivery) to permanently modify liver-expressed targets like PCSK9, ANGPTL3, and Lp(a).
|
$988.30M |
$11.13
|
|
Precigen's core programs are gene therapies (e.g., PRGN-2012), aligning with Biotech - Gene Therapy.
|
$959.34M |
$3.25
-3.85%
|
|
Core focus on gene therapy/gene editing workflows via nucleic acid production inputs and related technologies (CleanCap, Poly(A+) tail mods, CleanScribe).
|
$812.36M |
$3.19
-3.92%
|
|
UGN-501 oncolytic virus implies involvement in gene therapy/viral vector modalities.
|
$802.27M |
$17.40
+0.87%
|
|
In vivo fusogen/gene delivery platform and CRISPR editing collaboration indicate gene therapy modality and in vivo delivery capabilities.
|
$753.35M |
$3.34
-1.47%
|
|
Prime Medicine's core focus is gene-editing therapies (Prime Editing) intended as one-time curative genetic medicines, i.e., gene therapy.
|
$745.75M |
$5.68
-9.55%
|
|
Research into gene-edited/gene therapy-enhanced TIL platforms (IOV-4001) qualifies as gene therapy.
|
$737.99M |
$2.25
+2.04%
|
|
Core business: the company develops and commercializes gene therapies (AAV-GAD, AAV2-hAQP1, AIPL1) and a proprietary riboswitch platform.
|
$630.06M |
$7.84
-11.11%
|
|
REGENXBIO's core business revolves around NAV gene therapy platform and its in-house gene therapy product candidates (RGX-121, RGX-202, ABBV-RGX-314), mapping to Biotech - Gene Therapy.
|
$547.75M |
$10.92
-9.83%
|
|
Modifier gene therapy platform delivering NR2E3 and RORA indicates a gene therapy-focused modality.
|
$516.90M |
$1.79
+1.41%
|
|
ARCT-032 and ARCT-810 are mRNA-based therapies (gene therapy approach) targeting CF and OTC deficiency.
|
$513.94M |
$18.95
-5.11%
|
|
Solid is a gene therapy company developing multi-program viral-vector therapies (e.g., SGT-3.00 for DMD, SGT-212 for FA, SGT-501 for CPVT).
|
$461.99M |
$5.96
-7.31%
|
|
CAR-T therapy is a form of gene therapy leveraging engineered cells.
|
$441.79M |
$1.66
-6.21%
|
|
Neurogene is a clinical-stage biotechnology company that directly develops gene therapies (NGN-401) for neurological diseases, i.e., a gene therapy business line.
|
$430.86M |
$30.21
-4.28%
|
|
Lead asset detalimogene voraplasmid is a gene therapy delivered using a non-viral DDX platform, aligning with Biotech - Gene Therapy.
|
$428.77M |
$8.39
-5.20%
|
|
FDMT's core business is precision gene therapy developed on its Therapeutic Vector Evolution platform, with lead assets like 4D-150 and 4D-710.
|
$412.29M |
$8.90
-7.29%
|
|
Biotech - Gene Therapy: The RNA editing modality represents a gene therapy-like approach to treating diseases at the RNA level.
|
$403.51M |
$42.97
-8.18%
|
|
Silence and Replace delivers gene silencing plus wildtype gene replacement via AAV, core to gene therapy.
|
$381.96M |
$14.92
+5.89%
|
|
RPx uses engineered HSV-1 viral vectors delivering therapeutic genes, fitting Biotech - Gene Therapy.
|
$352.29M |
$4.67
+2.30%
|
|
Rocket’s core platform is viral-vector gene therapies (in vivo AAV and ex vivo LV) delivering genetic material to patients.
|
$351.23M |
$3.27
+0.46%
|
|
Tenaya is developing gene therapies (TN-201, TN-401) for cardiovascular genetic diseases using viral vectors, which directly maps to Biotech - Gene Therapy.
|
$341.60M |
$2.10
-5.19%
|
|
ASO-based VCA-894A indicates a gene-therapy/antisense oligonucleotide platform, aligning with Gene Therapy in Biotech.
|
$312.94M |
$5.31
-3.80%
|
|
Editas Medicine is a biotech company developing in vivo gene-editing therapeutics (gene therapy) using its Cas12a-based platform.
|
$311.41M |
$3.72
-11.85%
|
|
Lead programs are gene therapy vectors delivered by viruses ( HSV/adenovirus platforms ).
|
$310.14M |
$6.19
-6.07%
|
|
ADP064-ABC includes an anti-tau siRNA program enabled by the ABC platform, representing a gene-silencing/siRNA therapeutic approach.
|
$301.98M |
$3.02
-5.48%
|
|
VDC platform uses viral vectors (virus-like particles) to deliver cytotoxic payload, aligning with viral-vector/gene-therapy modality.
|
$297.59M |
$5.92
-2.95%
|
|
Proprietary TALEN gene-editing platform powering T-cell engineering and potential gene-editing therapies.
|
$291.26M |
$4.04
-3.81%
|
|
CAR T therapies involve genetic modification of cells, aligning with gene therapy categorization.
|
$286.54M |
$6.63
-5.69%
|
|
Core product category is gene therapies using TRACER capsids and payloads (e.g., VY7523, VY1706, APOE, SOD1) enabling IV-delivered CNS gene therapy.
|
$276.68M |
$5.00
-3.29%
|
|
ABEO's lead asset is a gene therapy product targeting recessive dystrophic epidermolysis bullosa (RDEB).
|
$273.18M |
$5.34
-1.11%
|
|
Uses TALEN gene-editing technology to create CAR T cells, aligning with gene therapy category.
|
$269.04M |
$1.23
-14.58%
|
|
Engineering of CAR-T cells involves genetic modification, which can fall under Gene Therapy within Biotech.
|
$262.11M |
$17.75
+11.99%
|
|
The company is pursuing an ENPP1 gene therapy construct (AAV) in preclinical development, representing a gene therapy modality in its pipeline.
|
$256.96M |
$4.00
|
|
The platform leverages genome editing of hematopoietic stem cells, aligning with gene therapy concepts.
|
$234.05M |
$37.46
+1.57%
|
|
Platform supports gene therapy/gene-delivery modalities, aligning with gene therapy investable theme.
|
$231.14M |
$6.09
-10.44%
|
|
Proprietary mRNAi GOLD platform enabling silencing via siRNA (RNA interference) as the core therapeutic modality.
|
$226.72M |
$1.60
|
|
Directly develops AAV-based gene therapies for cardiovascular and neurodegenerative genetic diseases (LX2006/LX2020).
|
$219.76M |
$6.62
-1.05%
|
|
Platform enables gene-editing therapeutics; Biotech - Gene Therapy.
|
$213.91M |
$2.30
+5.50%
|
|
ProQR's core Axiomer platform is a gene therapy–style RNA editing technology with clinical programs AX-0810 and AX-2402.
|
$203.04M |
$2.41
-3.98%
|
|
Olvi-Vec uses a modified vaccinia virus as a delivery/vector platform, aligning with gene therapy approaches.
|
$191.32M |
$5.07
-7.82%
|
|
Biotech - Gene Therapy: gene therapy development and delivery platforms enabled by non-viral methods.
|
$167.98M |
$1.66
+5.06%
|
|
Company's core platform is gene therapy using zinc finger and ZFR technologies, a direct gene therapy product category.
|
$156.76M |
$0.67
-10.35%
|
|
CER-T CAR-T therapies involve gene-modification aspects, aligning with Biotech - Gene Therapy.
|
$139.47M |
$4.33
-12.35%
|
|
TCR-T therapies involve genetic modification of T cells, aligning with gene therapy.
|
$125.07M |
$2.21
+0.45%
|
|
CAR T cell therapies involve genetic modification of cells, placing it within the gene therapy category.
|
$123.81M |
$2.44
-1.61%
|
|
Core business pivot to an AAV-based gene therapy platform with lead programs for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$116.94M |
$1.96
-2.97%
|
|
Directly develops a gene therapy product (Ixo-vec) for an ocular indication, using AAV-based delivery.
|
$112.60M |
$5.39
+0.09%
|
|
MGX is developing a gene therapy/gene editing platform (metagenomics-derived toolbox) with in vivo and ex vivo capabilities.
|
$106.91M |
$2.86
-8.04%
|
|
INOVIO's core DNA Medicines platform and SynCon/CELLECTRA approach represent its primary gene therapy technology for delivering therapeutic proteins in vivo.
|
$94.25M |
$2.57
-1.91%
|
|
Relates to gene-editing and armored cell therapy approaches used in ADI-212, reflecting gene therapy/modification aspects of the platform.
|
$80.00M |
$0.97
+5.13%
|
|
CAR-T cell therapy involves genetic modification of patient T-cells, aligning with gene therapy category in biotech.
|
$69.69M |
$2.50
-7.41%
|
|
Rejuva gene therapy platform (RJVA-001/002) represents a gene therapy program delivering AAV to the pancreas for long-term metabolic control.
|
$65.63M |
$1.34
-5.63%
|
|
ARCUS is a gene editing platform used for in vivo therapies, a core product/technology of Precision BioSciences, aligning with gene therapy as a major business segment.
|
$62.87M |
$5.67
+4.23%
|
|
Gene therapy–adjacent approach using RNA actuators to modulate gene expression, aligning with gene therapy-related modalities.
|
$61.09M |
$3.03
+1.00%
|
|
Genenta's core platform is gene therapy (hematopoietic stem cell gene therapy) targeting solid tumors.
|
$59.44M |
$3.25
-2.98%
|
|
Engineered iNKT programs (e.g., IL-15 armored CAR-iNKT) indicate gene-modified cell therapies as a significant development path.
|
$55.80M |
$14.00
-4.24%
|
|
SNAP-CAR and gene-editing approaches imply gene therapy modalities.
|
$55.17M |
$15.70
-1.94%
|
|
Viral-vector platform (ChAdOx and MVA) underpin Barinthus Bio's gene therapy initiatives, including VTP-300 HBV.
|
$54.86M |
$1.36
-4.90%
|
|
Genetic modification of patient T cells to express engineered receptors aligns with gene therapy category.
|
$49.11M |
$0.18
-9.80%
|
|
Senti's proprietary gene circuit platform engineers cells for therapeutic purposes, placing it in Biotech - Gene Therapy.
|
$44.08M |
$1.69
-11.05%
|
|
ctLNP/siRNA delivery platform enabling intracellular gene silencing in T cells for autoimmune indications (gene therapy modality).
|
$40.22M |
$5.72
-0.35%
|
|
PBFT02 is Passage Bio's lead gene therapy product, placing the company squarely in the Biotech - Gene Therapy category.
|
$26.32M |
$8.47
-5.57%
|
|
CytoMed's approach involves engineered cells (CARs on gamma delta T cells) which aligns with gene therapy concepts.
|
$23.77M |
$2.06
-8.44%
|
|
Provides healthcare-related composite parts and healthcare product applications.
|
$19.56M |
$1.15
-3.36%
|
|
Biotech - Gene Therapy represents another potential modality within the biotech portfolio mentioned in the article.
|
$15.41M |
$0.24
|
|
Exclusive KRAS gene-related license, aligning with biotech/gene therapy applications.
|
$13.32M |
$0.12
|
|
Gene therapy-related initiatives within the Biotechnology segment.
|
$11.75M |
$1.29
-4.30%
|
|
Engineering cells/macrophages involves genetic modification of cells; aligns with gene therapy as a therapeutic approach.
|
$10.90M |
$0.24
-6.09%
|
|
INTASYL includes gene-silencing approaches (e.g., BRD4 targeting), aligning with Biotech - Gene Therapy as a gene-modulation platform.
|
$10.57M |
$2.20
-7.09%
|
|
Sickle cell gene therapy mobilization data links motixafortide to gene therapy applications.
|
$9.38M |
$3.91
-5.10%
|
|
Biotech - Gene Therapy tag capturing potential for gene therapy modalities and related platform technologies.
|
$8.81M |
$10.56
-1.45%
|
|
PAVmed is pursuing early-stage biopharma assets, including gene-therapy programs, i.e., Biotech - Gene Therapy.
|
$8.61M |
$0.49
-13.83%
|
Showing page 1 of 2 (108 total stocks)
Loading industry metrics...
Loading comparison data...
